12:08 PM EST, 01/08/2025 (MT Newswires) -- The European stock markets closed mixed in Wednesday trading as The Stoxx Europe was down 0.27%, Germany's DAX was off 0.12%, the FTSE in London edged 0.07% higher, France's CAC declined 0.49%, and the Swiss Market Index gained 0.38%.

Industrial producer prices rose 1.6% in the euro area and 1.7% in the European Union in November, according to preliminary estimates from Eurostat, the statistical office of the EU. Compared with a year earlier, industrial producer prices were down 1.2% in the euro area and 1.1% in the EU.

In Germany, price adjusted retail sales rose 1.3% in 2024 and 2.7% in nominal terms compared with 2023, according to the Federal Statistical Office.

In France, the household confidence index declined to 89 in December from 90 the previous month, remaining below its long-term average of 100, according to the Institute of Statistics and Economic Studies.

And in corporate news, Deutsche Bank is planning to acquire a portfolio of bad loans for approximately $800 million from First Abu Dhabi Bank, Bloomberg reported Wednesday, citing unnamed sources with knowledge of the matter. Deutsche Bank declined MT Newswires' request for comment, while First Abu Dhabi Bank did not respond.

BP's M/s BP Exploration unit won a technical services provider contract from India's Oil and Natural Gas Corp to review the field performance and identify improvements in offshore Mumbai High Field as well as the facilities and wells to improve the production from the field, ONGC said in a regulatory filing Wednesday. BP did not immediately respond to requests for comment from MT Newswires. BP shares declined 0.38% on the FTSE.

Shell said it expects weaker Q4 oil and gas trading results compared with Q3 as a result of lower liquefied natural gas production, as well as weaker trading performance. Shares of the British oil and gas company closed 1.4% lower in London.

Novo Nordisk and Valo Health said Wednesday that they plan to discover and develop new treatments for obesity, type 2 diabetes, and cardiovascular disease. Shares of the Danish pharmaceutical giant rose 2.8% in Copenhagen trading.